Biohaven (NYSE:BHVN – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a research report issued on Thursday, Benzinga reports.
BHVN has been the subject of a number of other reports. UBS Group started coverage on shares of Biohaven in a report on Tuesday, February 6th. They issued a “buy” rating and a $59.00 target price for the company. HC Wainwright boosted their target price on shares of Biohaven from $50.00 to $63.00 and gave the company a “buy” rating in a report on Monday, March 4th. JPMorgan Chase & Co. boosted their price objective on shares of Biohaven from $32.00 to $56.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a research note on Tuesday, April 9th. Finally, TD Cowen boosted their price objective on shares of Biohaven from $35.00 to $55.00 and gave the stock an “outperform” rating in a research note on Friday, March 1st. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $52.00.
Check Out Our Latest Analysis on Biohaven
Biohaven Price Performance
Biohaven (NYSE:BHVN – Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). As a group, analysts expect that Biohaven will post -5.85 EPS for the current fiscal year.
Hedge Funds Weigh In On Biohaven
Large investors have recently bought and sold shares of the business. US Bancorp DE lifted its holdings in Biohaven by 19.1% in the first quarter. US Bancorp DE now owns 586 shares of the company’s stock worth $70,000 after acquiring an additional 94 shares during the last quarter. KBC Group NV bought a new position in Biohaven in the fourth quarter worth about $74,000. Advisor Group Holdings Inc. lifted its holdings in Biohaven by 219.8% in the fourth quarter. Advisor Group Holdings Inc. now owns 8,606 shares of the company’s stock worth $120,000 after acquiring an additional 5,915 shares during the last quarter. O Shaughnessy Asset Management LLC bought a new stake in shares of Biohaven during the first quarter valued at approximately $143,000. Finally, Creative Planning bought a new stake in shares of Biohaven during the fourth quarter valued at approximately $147,000. Institutional investors own 88.78% of the company’s stock.
Biohaven Company Profile
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
Further Reading
- Five stocks we like better than Biohaven
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Bear Market Funds to Watch This Year
- What Makes a Stock a Good Dividend Stock?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.